Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Voyager TherapeuticsFRA:VT6 -0.71%43 Cash-to-Debt is 3.57 as of Jun. 2026, which is 54% below its 10-year median of 7.76. GuruFocus rates FRA:VT6 with a GF Score™ of 43/100 and a GF Value™ of €1.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, Voyager Therapeutics ranks worse than 58.94% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Voyager Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.57.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Voyager Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Voyager Therapeutics's Cash-to-Debt or its related term are showing as below:
FRA:VT6'
s Cash-to-Debt Range Over the Past 10 Years
Min: 1.09 Med: 7.76 Max: No Debt
Current: 3.57
During the past 13 years, Voyager Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 1.09. And the median was 7.76.
FRA:VT6's Cash-to-Debt is ranked worse than 58.94% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs FRA:VT6: 3.57
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Voyager Therapeutics Cash-to-Debt Related Terms
Voyager Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Voyager Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:VT6 vs CHRS, KROS, DTIL: Cash-to-Debt Comparison
For the Biotechnology subindustry, Voyager Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Voyager Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Voyager Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Voyager Therapeutics (FRA:VT6) has a Cash-to-Debt of 3.57 as of Jun. 2026. This is 54% below median its historical median of 7.76. Over the past decade, Voyager Therapeutics' Cash-to-Debt has ranged from 1.09 to 10,000.00. According to the industry distribution chart, Voyager Therapeutics ranks #821 out of 1393 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Voyager Therapeutics' Cash-to-Debt too high?
Voyager Therapeutics' current Cash-to-Debt of 3.57 is 54% below median its 10-year median of 7.76. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Voyager Therapeutics' value of 3.57 is 49.2% below this industry median. Based on the distribution chart, Voyager Therapeutics ranks #821 out of 1393 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Voyager Therapeutics has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Cash-to-Debt compare to CHRS and KROS?
According to the Biotechnology industry distribution chart, Voyager Therapeutics ranks #821 out of 1393 companies for Cash-to-Debt. This places Voyager Therapeutics in the lower half of its industry. The industry median Cash-to-Debt is 7.03. Voyager Therapeutics' value of 3.57 is 49.2% below this benchmark. Historically, Voyager Therapeutics' own Cash-to-Debt has ranged from 1.09 to 10,000.00 over the past decade. While the company's 10-year median is 7.76 vs. the industry median of 7.03, Voyager Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Voyager Therapeutics's current Cash-to-Debt of 3.57 is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyager Therapeutics's current Cash-to-Debt is 3.57, which is 54% below median its own 10-year median of 7.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.11, compared to a current price of €2.53 — trading 127.9% above its estimated fair value. The current Cash-to-Debt is 3.57, which is 54% below median its 10-year median of 7.76 and 49.2% below the Biotechnology industry median of 7.03. Voyager Therapeutics' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Cash-to-Debt is 3.57 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?
Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued.
The current stock price of €2.53 is trading 127.9% above its estimated GF Value™ of €1.11.
GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:VT6:
Cash-to-Debt: 3.57 (54% below median its 10-year median of 7.76)
GF Value™: €1.11 vs. price of €2.53 (127.9% above fair value)
Industry Position: 49.2% below the Biotechnology median (#821 of 1393)
No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
43GF Score
Get the complete analysis for FRA:VT6
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VT6 has been successfully added to your 
